Why cystic fibrosis trial monitoring matters in 2026
Cystic fibrosis is one of the most commercially significant rare disease therapeutic areas. The CFTR modulator revolution, led by elexacaftor/tezacaftor/ivacaftor (Trikafta/Kaftrio), has transformed outcomes for the approximately 90% of CF patients with at least one F508del allele. But the remaining 10% of patients with rare mutations, plus the long-term question of whether modulators can fully prevent disease progression, means an active and commercially important pipeline continues.
Key signals in the CF pipeline for 2026 and beyond:
- Next-generation CFTR modulator combinations, triple and quadruple combinations targeting patients with minimal function mutations
- Gene therapy and gene editing programs targeting the underlying CFTR mutation for a potential functional cure
- mRNA replacement therapy, delivering functional CFTR mRNA to lung epithelial cells
- Complementary therapies alongside modulators: anti-inflammatory agents, mucociliary clearance, microbiome modulation
- Long-term complications management: CF-related diabetes (CFRD), bone disease, liver disease, fertility
- Pediatric dosing and safety studies as modulators expand to younger patients
Get daily CF trial digest
Set your profile once. Receive a filtered daily digest of new and updated CF trials. Free plan, no credit card required.
Get the Free DigestA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Real World Clinical Outcomes With Novel Modulator Therapy Combinations in… NCT04602468 | Primary completion moved at least 3 months later Primary endpoint reworded Enrollment reduced 13% | Active, Not Recruiting |
15 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination… NCT05444257 | Oct 30, 2026 · Estimated | Phase 3 |
4 more on the Completions page. See the calendar →
What DataLookout monitors for cystic fibrosis
Configure your profile with condition and mechanism keywords to match your intelligence needs:
- Condition keywords: "cystic fibrosis", "CF", "CFTR", "mucoviscidosis"
- Mechanism keywords: "CFTR modulator", "CFTR potentiator", "CFTR corrector", "gene therapy", "mRNA therapy", "gene editing"
- Complication-specific: "CF-related diabetes", "CFRD", "cystic fibrosis liver disease", "CF bone disease"
- Phase filter: Phase 2/3 for commercial and competitive intelligence, or all phases for comprehensive research coverage
- Sponsor filter: Industry-sponsored programs for BD relevance, NIH/academic for basic science developments
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Cystic Fibrosis trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
Who uses cystic fibrosis trial monitoring
Rare disease pharma BD and strategy teams
Companies active in CF, or seeking to enter the space, track new trial registrations to identify partnership opportunities and anticipate competitive challenges. With Vertex dominating the CFTR modulator market, the strategic questions center on whether gene therapy approaches can achieve the efficacy needed to displace highly effective modulators, and what the commercial opportunity looks like for the remaining unaddressed patient population.
CF-focused biotech analysts and investors
Investors covering rare pulmonary disease use trial registrations as pipeline intelligence. Gene therapy programs advancing into Phase 2 in CF represent significant capital events, and monitoring new trial activity allows analysts to track pipeline maturation ahead of major data readouts.
Cystic Fibrosis Foundation and patient advocacy networks
The CFF and patient advocacy organizations actively fund and monitor the CF research pipeline. Real-time awareness of new trial registrations enables advocates to connect patients, particularly those with rare mutations not addressable by current modulators, with appropriate clinical study opportunities.
Frequently asked questions
How current is the cystic fibrosis trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated as sponsors register new trials or submit protocol amendments.
Can I track CFTR modulator and gene therapy trials separately?
Yes. On Pro ($49/month, or $490/year), you can save up to 10 searches, for example, one monitoring CFTR modulator programs and another tracking gene therapy and mRNA approaches in CF, each delivering a focused daily digest.
Does DataLookout cover CF complications trials?
Yes. Adding keywords like "CF-related diabetes", "cystic fibrosis liver disease", or "CF bone disease" will surface trials targeting specific complications of cystic fibrosis alongside or separate from primary CFTR-targeting programs.
Does DataLookout cover pediatric CF trials?
Yes, pediatric dosing, safety, and efficacy studies registered on ClinicalTrials.gov are included. As CFTR modulators expand to younger age groups, tracking the associated clinical program is important for the field.
195 active trials, 118 recruiting.
Industry sponsors run 22 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 15.
| Top industry sponsor | Active trials |
|---|---|
| Vertex Pharmaceuticals | 8 |
| 4D Molecular Therapeutics | 1 |
| Aimmune Nestlé Health Science US R&D, LLC | 1 |
| Anagram Therapeutics, Inc. | 1 |
| Arcturus Therapeutics, Inc. | 1 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Regional Phenotyping of CF and Non-CF Bronchiectasis NCT04793867 | Recruiting | Completion pushed from Mar 31, 2027 to Dec 31, 2028 | 2026-10-08 |
| Exercise in Child Health NCT05359991 | Recruiting | Completion pushed from Jun 30, 2026 to Dec 31, 2027 | 2026-10-03 |
| A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult… NCT07559175 | Recruiting | Trial sites expanded: 30 → 39 locations | 2026-10-02 |
| A Prospective, Single-center, Open-label Study of Inhaled BMD003 (CFTR mRNA) in… NCT06963008 | Active, Not Recruiting | Primary completion pushed from May 10, 2026 to Dec 13, 2026 | 2026-10-02 |
| Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis… NCT07485543 | Recruiting | Recruitment opened | 2026-10-02 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.